Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Quarterly results
|
|
ADMA BIOLOGICS, INC. (ADMA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/09/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
8-K
| Quarterly results |
| 06/06/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
8-K
| Credit agreement amendment |
| 03/23/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"RAMSEY, N.J., BOCA RATON, Fla. and Hammond, LA. – February 8, 2023 – ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration approval for its eighth ADMA BioCenters plasma collection facility located in Hammond, Louisiana. This plasma collection facility commenced operations and initiated source plasma collection in the second quarter of 2022. With the FDA approval announced today, this facility is now licensed to collect, and introduce into interstate commerce, human source plasma for further manufacturing in the U.S. “The successful expansion of ADMA’s plasma collection network supports the Company’s goal of plas..." |
|
| 01/17/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"RAMSEY, N.J. and BOCA RATON, Fla., January 17, 2023 -- ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be approximately $49-50 million, an increase of approximately 89% over the fourth quarter of 2021, and full year 2022 preliminary, unaudited revenue of approximately $153-$154 million, an increase of approximately 90% over full year 2021." |
|
| 12/09/2022 |
8-K
| Quarterly results |
| 12/07/2022 |
8-K
| Quarterly results |
| 12/06/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/31/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
8-K
| Quarterly results |
| 06/27/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K
| Quarterly results |
| 06/13/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/25/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/24/2022 |
8-K
| Quarterly results|
Docs:
|
"RAMSEY, N.J. and BOCA RATON, Fla., March 24, 2022 -- ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its fourth quarter and full year 2021 financial results. Additionally, ADMA today announced the closing of a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to the achievement of certain revenue targets during 2022. The first tranche of the newly issued loan from Hayfin was fully drawn and used to completely repay the obligations under the Perceptive Advisors senior secured notes, including all associated prepayment fees." |
|
| 03/09/2022 |
8-K
| Quarterly results |
| 03/07/2022 |
8-K
| Quarterly results |
| 01/19/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"RAMSEY, N.J. and BOCA RATON, Fla., January 19, 2022 -- ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its preliminary unaudited fourth quarter and full year 2021 revenues. The Company also provided commercial updates for its immune globulin product portfolio as well as 2022 business updates. Based on preliminary unaudited financial information, ADMA expects record fourth quarter 2021 revenues of approximately $26 million, compared to $14 million during the fourth quarter of 2020, reflecting an approximate 86% increase. The preliminary results for the fourth quarter of 2021 represent the Company’s highest quarterly revenue since its inception. For full year 202..." |
|
| 01/18/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"RAMSEY, N.J., BOCA RATON, Fla. and GOOSE CREEK, SC. – January 18, 2022 – ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration approval for its fourth ADMA BioCenters plasma collection facility located in Goose Creek, South Carolina. In conjunction, the facility was issued a compliance certification from the International Quality Plasma Program , confirming the center meets facility and donor criteria for IQPP Certification. This plasma collection facility commenced operations and initiated source plasma collection in the second quarter of 2021. With today’s approval, this facility is now FDA-licensed to collect ..." |
|
| 12/21/2021 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...|
Docs:
|
"Amended and Restated Certificate of Designation of Series A Junior Participating Preferred Stock of ADMA Biologics, Inc",
"Rights Agreement, by and between ADMA Biologics, Inc. and Continental Stock Transfer and Trust Company, as rights agent",
"RAMSEY, N.J. and BOCA RATON, Fla., December 21, 2021 – ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors has approved the adoption of a 6-month term stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock. The record date for the dividend distribution is December 30, 2021. The Rights Plan will expire, without any further action required to be taken by ADMA’s Board of Directors, on June 15, 2022." |
|
| 12/09/2021 |
8-K
| Quarterly results |
| 12/01/2021 |
8-K
| Investor presentation |
| 11/16/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"RAMSEY, N.J., BOCA RATON, FL and Myrtle Beach, SC – November 16, 2021 – ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters location in Myrtle Beach, South Carolina. “ADMA continues to successfully advance its ADMA BioCenters expansion strategy, and in doing so, we believe is well-positioned to ensure continuity of plasma supply to support the significant revenue growth targets for the Company’s commercial Immune Globulin portfolio,” said Adam Grossman, President and Chief Executive Officer of ADMA. “With the opening of this Myrtle Beach plasma collection center, ADMA ..." |
|
| 11/10/2021 |
8-K
| Quarterly results|
Docs:
|
"RAMSEY, NJ and BOCA RATON, FL – November 10, 2021 – ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for the three months ended September 30, 2021, its fiscal third quarter, and provided an overview of recent progress and accomplishments. “Achieving a positive gross profit and 101% year-over-year revenue growth represents a key inflection point for the Company as we continue our ongoing commercial and production ramp up. These financial milestones and accomplishments would not have been possible without the dedication and focus of ADMA’s staff, leadership and advisors. We commend the entire team for their extraordinary efforts focused on improvi..." |
|
| 10/25/2021 |
8-K
| Asset disposition|
Docs:
|
"Opinion of Morgan, Lewis & Bockius LLP",
"RAMSEY, NJ and BOCA RATON, FL, October 25, 2021 -- ADMA Biologics, Inc. , an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, in addition to the exercise in full of the underwriters’ option to purchase an additional 7.5 million shares of common stock. The gross proceeds from the exercise of the overallotment option were $7.5 million, bringing the total gross proceeds to ADMA from the offering to $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses." |
|
| 10/21/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 10/20/2021 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits Interactive Data |
|
|
|